Thu, Feb 26, 2015, 7:47 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • upsidedownnow upsidedownnow Aug 7, 2013 5:30 PM Flag

    Buying opportunity......

    Nothing wrong with ARRY's drug. Amgen is gathering all the cash it can because of it's plan to bid for Onyx Pharma. Let's wait and see.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think that AMG151 actually failed in the clinic - Amgen cancelled their Phase II trial some time ago. But nobody was counting on it anyway, Array last mentioned it a year ago as a 8.5M milestone source. All Array was touting since then is their oncology/inflammation pipeline. No big deal for Amgen, they bid 75M on it and lost - pocket money for the company. No big deal for Array - this drug was outside of their core competency and a long shot at diabetes market.
      Overall, the layoff is a slightly positive news - cuts the burn rate once again, turns the corner towards profitability. Earnings release is also slightly positive - nobody really cares about beating estimates too much, but analysts like to see predictability and sticking to the guidance from the management. I expect ARRY to open tomorrow flat or up from the close price.

    • You're not really serious are you ?

      AMGN is an $85 BILLION dollar market cap company, these milestones to ARRY weren't even coffee break money to them, it's very obvious they see it's a waste to them, even a small waste is still a waste.

      So they back out of the deal.

      Simple as that.

8.11-0.01(-0.12%)Feb 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.